Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical methylprednisolone + bupivacaine for dysphagia after ACDF
IRCT20250814066853N1Phase 3Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jun 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of methylprednisolone and bupivacaine in Cervical discopathy (CDDD) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Postoperative dysphagia severity, Postoperative odynophagia severity and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
methylprednisolonebupivacaine
03
Conditions
Cervical discopathy (CDDD)
Beyond the preview
Go deeper on IRCT20250814066853N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250814066853N1.